Case series of low dose rituximab for membranous nephropathy; a single centre experience

Introduction: Rituximab is the recent treatment of choice for primary membranous nephropathy However, dose rituximab mentioned in literature high and not economical middle income countries. Low based on CD 19 cell count can be tried as an alternative inducing clinical remission appropriate settings. Case Series: Four patients were administered low initial was monitored optimal response. Three males one female are part this case series. Renal biopsies showed with tissue phospholipase A2 receptor (PLA2R) positivity two cases. Serum PLA2R positive same Two completely remitted after year, male patient required additional CD19 count, single partial background tacrolimus steroids. One failed to remit protocol. Conclusion: a favorable